INMB Company Profile and Key Details

Q: Who are the executives of INMB?

Mr. Joshua S. Schoonover Esq.Assoc. Gen. CounselMr. David J. Moss M.B.A.Chief Financial Officer, Treasurer & Sec.Dr. Raymond Joseph Tesi M.D.Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & ChairmanDr. Christopher J. BarnumHead of Neuroscience

NASDAQ : INMB

INmune Bio

$1.93

-0.04-2.03%

Open: 9:53 AM

61.13

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

INmune Bio, Inc. (INMB) stock declined over -2.03%, trading at $1.93 on NASDAQ, down from the previous close of $1.97. The stock opened at $1.98, fluctuating between $1.93 and $1.98 in the recent session.

Stock Snapshot

1.97

Prev. Close

51.31M

Market Cap

1.93

Day Low

-2.01

P/E Ratio

-0.96

EPS (TTM)

-0.67

Cash Flow per Share

1.98

Open

26.59M

Number of Shares

1.98

Day High

70.43%

Free Float in %

2.12

Book Value

19.37K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 21, 2026	2.00	2.04	1.91	1.97	434.41K
Jul 20, 2026	1.88	2.08	1.88	1.99	453.55K
Jul 17, 2026	2.07	2.07	1.85	1.90	796.53K
Jul 16, 2026	2.06	2.10	1.99	2.07	517.89K
Jul 15, 2026	2.08	2.17	1.98	2.07	1.07M
Jul 14, 2026	1.85	2.08	1.82	2.02	1.04M
Jul 13, 2026	1.88	1.99	1.81	1.86	1.08M
Jul 10, 2026	1.79	1.97	1.74	1.94	1.59M
Jul 09, 2026	1.73	1.79	1.66	1.79	1.28M
Jul 08, 2026	1.73	1.78	1.65	1.72	722.7K
Jul 07, 2026	1.67	1.85	1.54	1.74	1.79M
Jul 06, 2026	1.70	1.75	1.65	1.67	625.29K
Jul 02, 2026	1.72	1.74	1.63	1.70	964.21K
Jul 01, 2026	1.62	1.73	1.62	1.68	756.72K
Jun 30, 2026	1.58	1.71	1.58	1.63	526.92K
Jun 29, 2026	1.45	1.69	1.41	1.62	1.36M
Jun 26, 2026	1.49	1.59	1.42	1.42	3.38M
Jun 25, 2026	1.37	1.58	1.30	1.49	12.3M
Jun 24, 2026	1.43	1.54	1.35	1.35	272.66K
Jun 23, 2026	1.39	1.50	1.39	1.42	418.23K

Contact Details

Boca Raton, FL 33432

United States

https://www.inmunebio.com 858 964 3720

About Company

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Stock Peers

ARGX

28.55+3.37%

argenx SE$874.74 REGN

3.04+0.45%

Regeneron Pharmaceuticals, Inc.$675.19 MDGL

11.1+2.07%

Madrigal Pharmaceuticals, Inc.$546.79 UTHR

6.49+1.23%

United Therapeutics Corporation$535.83 VRTX

1.5+0.31%

Vertex Pharmaceuticals Incorporated$482.00 KRYS

-0.16-0.05%

Krystal Biotech, Inc.$339.06 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

8.11+2.61%

BeOne Medicines AG$318.69 PRAX

13.44+4.41%

Praxis Precision Medicines, Inc.$317.87 LGND

11.48+3.90%

Ligand Pharmaceuticals Incorporated$305.47

Company Overview

INmune Bio, Inc. (NASDAQ:INMB) closed at $1.93 USD, losing -$0.04 (-2.03%) from the previous close of $1.97. The stock is currently mid-range between its 52-week high and low $1.09 and $3.24. With a market capitalization of about $51.31 million, INmune Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.98). Key stats such as the average daily volume over the past year has been around 905.74 thousand shares, volume is running light vs its 52-week average. Headquartered in Boca Raton, FL, INmune Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David J. Moss, the company employs approximately 21 people and listed since February 04, 2019. INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies.

Technical Performance

INMB has shown mixed momentum, gaining 8.84% over the past week and -13.51% over the past quarter, though year-to-date performance is up 2.56%. Short-term trend indicators are bullishly aligned (SMA20 -7.78%, SMA50 -15.21%, SMA200 -52.41%). The stock’s 14-day RSI is 40.47 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -88.49% below its high and over 10.73% above its low. Average 10-day trading volume of 770.97 thousand shares is in line with the 3-month average of 774.48 thousand, indicating normal recent market interest.

Valuation Metrics

INmune Bio, Inc. trades at a P/E ratio of -1.14, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.62 suggesting the stock is closer to book value. The P/FCF stands at -2.48, also above market averages.

Dividend & Fair Value

INmune Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.83. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

INmune Bio, Inc. generated EPS of -$2.14 over the past year. Five-year average earnings growth is -23.07%. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.31. Next year's EPS is expected at -$41.69. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers 356.85% upside. The low target suggests 356.85% downside. The mean target is $9.00. This offers 356.85% upside. INmune Bio, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -18.37%. The prior quarter beat by -33.33%. Over the last six quarters, Apple has recorded several small beats. These include -25.93% in March 27, 2025.

Shareholding & Insider Activity

INmune Bio, Inc. has 26.59 million shares outstanding. The public float is 18.72 million shares, elevated short interest at 26.34% of float. This equals 5.98 million shares. The short ratio is 1.42 days. Institutional investors hold 22.18% of the float. Insiders own 11.23%. Moss David J holds 1.29 million shares, Powers Linda F has 210.00 thousand shares and Schroeder Timothy j has 82.19 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, INmune Bio generated $155.00K in revenue, or $0.01 per share. Gross margin was 100.00%, operating margin -19187.74%, and net profit margin -19360.00%. Returns are negative, with ROA at -52.64% and ROE at -78.68%.
On valuation metrics, INmune Bio trades at a P/E of -1.14, P/S of 0.00 and P/B of 2.62. The current ratio is 4.24 and quick ratio is 4.24. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -15745.69 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.08, supported by a cash flow-to-debt ratio of -12.70.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, INmune Bio posted revenue of $155.00K, down slightly from $374.00K in the prior quarter. Gross profit was $155.00K (margin 100.00%). Operating income was - $29.74M (margin -19187.7%). Net income was- $30.01M (EPS - $1.67).
The company ended the quarter with $35.85M in cash and short-term investments, a total debt of $10.44M, and net debt of - $25.41M. Total assets were $57.00M, with equity of $38.14M. Financials further reflected weakness, with operating cash flow of - $11.98M, free cash flow of - $11.98M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that INmune Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.27%, with price expected at $2.33 by August 04, 2026, within a range of $2.25 to $2.42 3-Month Outlook: Projected rise of 488.32%, reaching $11.59 by October 19, 2026, with a range of $10.60 to $12.64. 1-Year Outlook: Projected loss of -11.17%, with price at $1.75 by July 21, 2027, within a range of $0.00 to $0.00.

Key Takeaways

INmune Bio, Inc. (NASDAQ:INMB) shares are flat 2.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows INmune Bio, Inc. trading at a premium to the broader market with a P/E of -1.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.97, suggesting 913.71% upside. Our AI forecast model points to short-term strength (18.27% over two weeks), a medium-term rise (488.32% over three months), and a longer-term loss (-11.17% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current INmune Bio, Inc. (INMB) stock price?

INmune Bio, Inc. (NASDAQ: INMB) stock price is $1.93 in the last trading session. During the trading session, INMB stock reached the peak price of $1.98 while $1.93 was the lowest point it dropped to. The percentage change in INMB stock occurred in the recent session was -2.03% while the dollar amount for the price change in INMB stock was - $0.04.

INMB's industry and sector of operation?

The NASDAQ listed INMB is part of Biotechnology industry that operates in the broader Healthcare sector. INmune Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INMB?

Mr. Joshua S. Schoonover Esq.
Assoc. Gen. Counsel
Mr. David J. Moss M.B.A.
Chief Financial Officer, Treasurer & Sec.
Dr. Raymond Joseph Tesi M.D.
Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & Chairman
Dr. Christopher J. Barnum
Head of Neuroscience

How INMB did perform over past 52-week?

INMB's closing price is 80.73% higher than its 52-week low of $1.09 where as its distance from 52-week high of $3.24 is -39.27%.

How many employees does INMB have?

Number of INMB employees currently stands at 21.

Link for INMB official website?

Official Website of INMB is: https://www.inmunebio.com

How do I contact INMB?

INMB could be contacted at phone 858 964 3720 and can also be accessed through its website. INMB operates from 225 NE Mizner Boulevard, Boca Raton, FL 33432, United States.

How many shares of INMB are traded daily?

INMB stock volume for the day was 19.37K shares. The average number of INMB shares traded daily for last 3 months was 905.74K.

What is the market cap of INMB currently?

The market value of INMB currently stands at $51.31M with its latest stock price at $1.93 and 26.59M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	21
Beta	0.98
Sales or Revenue	$155.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

INMB Company Profile and Key Details

INmune Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways